Clinical Performance Evaluation of Ambu AuraGain versus I-gel in Obese Female Patients Undergoing Short-duration Surgeries for Breast Cancer: A Randomised Controlled Trial
Journal of Onco-Anaesthesiology and Perioperative Medicine · 2024
DOI: 10.4103/joapm.joapm_14_24 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Journal of Onco-Anaesthesiology and Perioperative Medicine, 2024. Verfasst von Suparna Mitra und 5 weiteren Autor:innen. Die Arbeit nennt 20 Literaturangaben.
Abstract (Originalsprache)
Background and Aims: Supraglottic airway devices (SADs) secure and maintain airways in patients undergoing breast cancer surgery. I-gel and Ambu AuraGain (AAG) are two common second-generation SADs used. However, data comparing their efficacy are limited in adult obese breast cancer patients. This study was planned with the primary objective of comparing the oropharyngeal leak pressure (OLP) of these two SADs at 1 min after insertion.
Methods
A total of 80 patients scheduled for breast cancer surgery were recruited and randomised into two groups: Group A (AAG) and Group I (I-gel). The insertion time of the SADs, the number of insertion attempts, the OLP at 1 min after insertion, the ease of insertion, the fibre-optic bronchoscopy view (FOB), the ease of suction catheter placement, additional manipulation during insertion and maintenance, the OLP at 30 min after insertion and complications, etc., were assessed.
Results
OLP was significantly higher ( P < 0.05) in Group I compared to Group A at 1 min and 30 min after the SAD placement. Ease of insertion and FOB view score were significantly better in Group I than in Group A ( P < 0.05). Moreover, patients in Group A reported a higher incidence of sore throat compared to Group I patients ( P < 0.05).
Conclusion
The I-gel demonstrated superior sealing pressures and mitigated sore throat significantly compared to the AAG in obese female patients undergoing breast cancer surgery. Furthermore, as confirmed by FOB, its enhanced perilaryngeal positioning underscores its efficacy over the AAG in this patient demographic.
Zitieren
APA
Mitra, S., Banerjee, S. S., Debroy, D., Nandi, R., Rudrapal, A., & Goswami, J. (2024). Clinical Performance Evaluation of Ambu AuraGain versus I-gel in Obese Female Patients Undergoing Short-duration Surgeries for Breast Cancer: A Randomised Controlled Trial. Journal of Onco-Anaesthesiology and Perioperative Medicine. https://doi.org/10.4103/joapm.joapm_14_24
Vancouver
Mitra S, Banerjee SS, Debroy D, Nandi R, Rudrapal A, Goswami J. Clinical Performance Evaluation of Ambu AuraGain versus I-gel in Obese Female Patients Undergoing Short-duration Surgeries for Breast Cancer: A Randomised Controlled Trial. Journal of Onco-Anaesthesiology and Perioperative Medicine. 2024. doi:10.4103/joapm.joapm_14_24
BibTeX
@article{Mitra2024,
author = {Mitra, Suparna and Banerjee, Sumantra Sarathi and Debroy, Debashis and Nandi, Rudranil and Rudrapal, Angshuman and Goswami, Jyotsna},
title = {Clinical Performance Evaluation of Ambu AuraGain versus I-gel in Obese Female Patients Undergoing Short-duration Surgeries for Breast Cancer: A Randomised Controlled Trial},
journal = {Journal of Onco-Anaesthesiology and Perioperative Medicine},
year = {2024},
doi = {10.4103/joapm.joapm_14_24}
}
EUVIMED